Cited by 494

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS

Drummond, Daryl C., Noble, Charles O., Kirpotin, Dmitri B., Guo, Zexiong, Scott, Gary K., Benz, Christopher C.·2005·Annual Review of Pharmacology and Toxicology

DOI 10.1146/annurev.pharmtox.45.120403.095825

Open this paper in CoChat — free account

Abstract

▪ Abstract Acetylation is a key posttranslational modification of many proteins responsible for regulating critical intracellular pathways. Although histones are the most thoroughly studied of acetylated protein substrates, histone acetyltransferases (HATs) and deacetylases (HDACs) are also responsible for modifying the activity of diverse types of nonhistone proteins, including transcription factors and signal transduction mediators. HDACs have emerged as uncredentialed molecular targets for the development of enzymatic inhibitors to treat human cancer, and six structurally distinct drug classes have been identified with in vivo bioavailability and intracellular capability to inhibit many of the known mammalian members representing the two general types of NAD+-independent yeast HDACs, Rpd3 (HDACs 1, 2, 3, 8) and Hda1 (HDACs 4, 5, 6, 7, 9a, 9b, 10). Initial clinical trials indicate that HDAC inhibitors from several different structural classes are very well tolerated and exhibit clinical activity against a variety of human malignancies; however, the molecular basis for their anticancer selectivity remains largely unknown. HDAC inhibitors have also shown preclinical promise when combined with other therapeutic agents, and innovative drug delivery strategies, including liposome encapsulation, may further enhance their clinical development and anticancer potential. An improved understanding of the mechanistic role of specific HDACs in human tumorigenesis, as well as the identification of more specific HDAC inhibitors, will likely accelerate the clinical development and broaden the future scope and utility of HDAC inhibitors for cancer treatment.

Integrity signals

Registry

Crossref · 10.1146/annurev.pharmtox.45.120403.095825

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Active Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253

Show all 6 references

Research works printed but not linked: 176

10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7 · DOI
Glaser KB, 2003, Mol. Cancer Ther., 2, 151
Van Lint C, 1996, Gene Expr., 5, 245
10.1016/S0092-8674(02)01080-2 · DOI · Paper page
10.1038/47412 · DOI · Paper page
10.1128/MMBR.64.2.435-459.2000 · DOI
10.1016/S0962-8924(01)02001-3 · DOI
10.1016/S0955-0674(02)00335-6 · DOI
10.1016/S0092-8674(03)00355-6 · DOI
10.1002/bies.10038 · DOI
10.1073/pnas.2436173100 · DOI
10.1002/jcb.10286 · DOI
10.1016/S0304-3835(02)00511-6 · DOI
10.1038/sj.onc.1206814 · DOI
10.1023/A:1022927725945 · DOI
10.1016/S0960-9822(02)01387-8 · DOI
10.1126/science.1063127 · DOI · Paper page
10.1038/nature01126 · DOI
10.1385/MB:17:1:01 · DOI
10.1093/emboj/20.18.5232 · DOI
10.1016/S0092-8674(02)01005-X · DOI
10.1016/S0092-8674(02)01077-2 · DOI
10.1016/S1097-2765(03)00224-7 · DOI
10.1016/S0960-9822(06)00296-X · DOI
10.1074/jbc.M000202200 · DOI
10.1128/MCB.23.23.8563-8575.2003 · DOI
10.1074/jbc.M100800200 · DOI
10.1093/emboj/19.17.4676 · DOI
10.1038/25166 · DOI · Paper page
10.1128/MCB.19.5.3466 · DOI
10.1038/89668 · DOI
10.1074/jbc.M107631200 · DOI
10.1128/MCB.21.17.5992-6005.2001 · DOI
10.1006/excr.2000.5080 · DOI
10.1016/S0960-9822(00)00542-X · DOI
10.1042/bj20021321 · DOI · Paper page
10.1073/pnas.96.9.4868 · DOI · Paper page
10.1074/jbc.M212935200 · DOI
10.1124/jpet.103.055541 · DOI
10.2174/0929867013372058 · DOI
10.1021/jm0303094 · DOI
10.2174/0929867013373787 · DOI
10.1038/43710 · DOI · Paper page
10.1002/1522-2675(20000809)83:8<1685::AID-HLCA1685>3.0.CO;2-4 · DOI · Paper page
10.1021/jm020154k · DOI
10.1002/bies.950170510 · DOI
10.1021/jm00384a013 · DOI
10.1517/13543784.9.12.2923 · DOI
Furumai R, 2002, Cancer Res., 62, 4916
Komatsu Y, 2001, Cancer Res., 61, 4459
el-Beltagi HM, 1993, Cancer Res., 53, 3008
10.1021/jm980565u · DOI
10.1021/jm011088+ · DOI
10.1021/jm031036f · DOI
10.1021/jo034248t · DOI
10.1016/S1074-5521(03)00095-4 · DOI
10.1073/pnas.0430973100 · DOI · Paper page
10.1038/sj.onc.1204299 · DOI
10.1007/PL00000896 · DOI
10.1038/35106079 · DOI · Paper page
10.1517/13543784.13.1.21 · DOI
10.1073/pnas.180316197 · DOI · Paper page
10.1097/00001813-200201000-00001 · DOI · Paper page
10.1073/pnas.2536759100 · DOI
10.1182/blood-2001-12-0368 · DOI
Han JW, 2000, Cancer Res., 60, 6068
10.1073/pnas.96.8.4592 · DOI
10.1038/5047 · DOI
10.1002/ijc.10789 · DOI
10.1016/S1368-7646(03)00067-0 · DOI
10.1016/S1535-6108(03)00165-X · DOI
10.1074/jbc.M106699200 · DOI
10.1165/ajrcmb.25.5.4539 · DOI
10.1007/BF02479423 · DOI
10.1097/00001622-199901000-00003 · DOI
Nimmanapalli R, 2003, Cancer Res., 63, 5126
Scott GK, 2002, Mol. Cancer Ther., 1, 385
Fuino L, 2003, Mol. Cancer Ther., 2, 971
10.1046/j.1365-2141.2003.04759.x · DOI
10.1182/blood-2003-03-0737 · DOI
Rahmani M, 2003, Cancer Res., 63, 8420
Liu LT, 2003, Cancer Res., 63, 3069
10.1016/S0006-2952(03)00411-8 · DOI
10.1124/mol.65.3.520 · DOI
10.1002/ijc.10327 · DOI
10.1002/ijc.10921 · DOI
10.1182/blood.V100.3.1008 · DOI
10.1182/blood.V96.9.3200 · DOI
10.1002/ijc.10998 · DOI
Peart MJ, 2003, Cancer Res., 63, 4460
10.1182/blood-2002-02-0567 · DOI
10.1093/nar/29.14.3006 · DOI
10.1002/jcp.1087 · DOI
Vigushin DM, 2001, Clin. Cancer Res., 7, 971
Svechnikova I, 2003, Int. J. Oncol., 22, 579
10.1016/S0304-3835(03)00184-8 · DOI
10.1021/jm030235w · DOI
10.1038/sj.bjc.6601510 · DOI
10.1111/j.1349-7006.2001.tb01126.x · DOI
Butler LM, 2001, Clin. Cancer Res., 7, 962
Butler LM, 2000, Cancer Res., 60, 5165
Arts J, Van Emelen K, Angibaud P, Van Brandt S, Poncelet V, et al. 2003. Small molecule inhibitors of histone deacetylases(HDACs):identification of JNJ16241199, a potent oral antitumoral agent. Presented at AACR-NCI-EORTC Int. Conf. Mol. Targets Cancer Ther., Boston
10.1182/blood.V98.9.2865 · DOI
10.1023/A:1006049227744 · DOI
Patnaik A, 2002, Clin. Cancer Res., 8, 2142
Jaboin J, 2002, Cancer Res., 62, 6108
Fournel M, 2002, Cancer Res., 62, 4325
10.1007/s00280-004-0783-4 · DOI
Sandor V, 2002, Clin. Cancer Res., 8, 718
10.1023/A:1006489328324 · DOI
Kelly WK, 2003, Clin. Cancer Res., 9, 3578
10.1182/blood.V98.9.2865 · DOI
10.1158/0008-5472.CAN-03-2043 · DOI
Drummond DC, 1999, Pharmacol. Rev., 51, 691
Benz C, 2003, Clin. Cancer Res., 9, 6259s
Kim MS, 2003, Cancer Res., 63, 7291
Witzig TE, 2000, Clin. Cancer Res., 6, 681
Zhu WG, 2001, Cancer Res., 61, 1327
10.1038/sj.onc.1204269 · DOI
10.1038/sj.onc.1206646 · DOI
10.1038/sj.leu.2402535 · DOI · Paper page
10.1023/A:1026146524737 · DOI
Coffey DC, 2001, Cancer Res., 61, 3591
Belinsky SA, 2003, Cancer Res., 63, 7089
10.1038/sj.leu.2401508 · DOI · Paper page
10.1182/blood.V99.4.1356 · DOI
Giuliano M, 1999, Cancer Res., 59, 5586
Yu C, 2003, Cancer Res., 63, 2118
10.1182/blood-2002-08-2675 · DOI
10.1124/mol.65.3.571 · DOI
Rosato RR, 2002, Mol. Cancer Ther., 1, 253
10.1067/mtc.2003.180 · DOI
10.1093/hmg/ddg204 · DOI
Pili R, 2001, Cancer Res., 61, 1477
Rosato RR, 2001, Int. J. Oncol., 19, 181
10.1158/1078-0432.CCR-0901-3 · DOI
10.1016/S0022-5223(03)01321-7 · DOI
10.1002/ijc.20117 · DOI
10.4161/cbt.3.3.698 · DOI
10.1172/JCI0216547 · DOI
10.1016/S0092-8674(00)80521-8 · DOI · Paper page
10.1038/sj.onc.1203329 · DOI
10.1016/S1097-2765(00)80145-8 · DOI
10.1038/26785 · DOI
10.1074/jbc.M312850200 · DOI
10.1073/pnas.95.17.9855 · DOI · Paper page
10.1016/S0092-8674(00)80054-9 · DOI
10.1016/S1097-2765(00)80253-1 · DOI
10.1016/S0960-9822(00)00445-0 · DOI
10.1007/s00109-003-0469-0 · DOI
10.1128/MCB.23.17.6243-6254.2003 · DOI
10.1074/jbc.M104427200 · DOI
10.1016/S1097-2765(04)00094-2 · DOI
10.1016/S1097-2765(00)00104-0 · DOI
10.1074/jbc.M305961200 · DOI
10.1093/emboj/19.24.6792 · DOI
10.1128/MCB.21.17.5979-5991.2001 · DOI
10.1093/emboj/19.4.662 · DOI
10.1016/S1097-2765(00)80383-4 · DOI
10.1074/jbc.M106451200 · DOI
Lee BI, 2001, Cancer Res., 61, 931
10.1073/pnas.182372299 · DOI
10.1038/86507 · DOI
10.1007/s00262-001-0239-1 · DOI
10.4161/cbt.3.5.985 · DOI
10.1038/sj.cdd.4400914 · DOI
Huang H, 1999, Cancer Res., 59, 2981
Yang X, 2000, Cancer Res., 60, 6890
10.1210/endo.142.9.8380 · DOI
Pawel JV, 2002, Am. Soc. Clin. Oncol. Annu. Meet., A1239,
10.1074/jbc.C000824200 · DOI
10.1158/0008-5472.CAN-03-2631 · DOI
10.1080/1042819031000149304 · DOI
10.1067/msy.2001.115897 · DOI
Rosato RR, 2003, Mol. Cancer Ther., 2, 1273
10.1158/0008-5472.CAN-03-2629 · DOI

Sorted by citations

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation
Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation
Pruitt, K., Zinn, R. L., Ohm, J. E., McGarvey, K. M., Kang, S.-H. L., Watkins, D. N., Herman, J. G., & Baylin, S. B. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020040 · Cited by 387
Histone Deacetylase Inhibitors Induce VHL and Ubiquitin-Independent Proteasomal Degradation of Hypoxia-Inducible Factor 1α
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0188 · Cited by 260
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Sodium butyrate ameliorates the impairment of synaptic plasticity by inhibiting the neuroinflammation in 5XFAD mice
Jiang, Y., Li, K., Li, X., Xu, L., & Yang, Z. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109452 · Cited by 154
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells
Scuto, A., Kirschbaum, M., Kowolik, C., Kretzner, L., Juhasz, A., Atadja, P., Pullarkat, V., Bhatia, R., Forman, S., Yen, Y., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117762 · Cited by 141
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
LaBonte, M. J., Wilson, P. M., Fazzone, W., Groshen, S., Lenz, H.-J., & Ladner, R. D. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-67 · Cited by 99
Sex Differences in Brain Epigenetics
Menger, Y., Bettscheider, M., Murgatroyd, C., & Spengler, D. (2010) · Epigenomics · doi:10.2217/epi.10.60 · Cited by 82
Histone deacetylase 1 activates PU.1 gene transcription through regulating TAF9 deacetylation and transcription factor IID assembly
Jian, W., Yan, B., Huang, S., & Qiu, Y. (2017) · The FASEB Journal · doi:10.1096/fj.201700022r · Cited by 23
New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20

Authors: Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C.
Affiliations: Hermes Biosciences, Inc., South San Francisco, California 94080
California Pacific Medical Center-Research Institute, San Francisco, California 94115
Buck Institute for Age Research, Novato, California 94945
Venue: Annual Review of Pharmacology and Toxicology
Publisher: Annual Reviews
Published: 2005-09-22
Volume: 45
Issue: 1
Pages: 495-528
ISSN: 0362-1642
1545-4304
DOI: 10.1146/annurev.pharmtox.45.120403.095825
Cited by: 494
References: 6
Language: en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks